

## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	P	IRST NAMED APPL	ICANT	ATTORNEY DOCKET NO.
063285	8-2-79	KEITH (	C. MURDOCK	ET A	AL. 27,962
EDWARD A. C 1937 WEST M STAMFORD, C	MAIN ST.				Goldberg ART UNIT PAPER NUMBER  A125 13 ATEMAILED:
This is a communication from the examiner in charge of your application.  JAN 8 (981)					
COM	MMISSIONER OF PAT				
* This application h		Presponsive to c	ommunication filed	on 9	ROUP 120.  Ly /80 + 149/F6 = 12/5/80  Ly /80 + 14/5/80  Ly /80 + 1
A shortened statutory period for response to this action is set to expire month(s), days from the date of this letter.  Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133					
Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:					
<ol> <li>Notice of References Cited by Examiner, PTO-892</li> <li>Notice of Informal Patent Drawing, PTO-948</li> <li>Notice of References Cited by Applicant, PTO-1449</li> <li>Notice of Informal Patent Application, Form PTO-152</li> </ol>					
Part II SUMMARY	Su -110	5			are pending in the application.
Of the abov	e, claims				are withdrawn from consideration
2. Claims					
3. 🔀 Claims 🌋	4-110 if in	INDEPER	DENT FOR	em,	are allowed.
4. 🔀 Claims <u>&amp;</u>	12+83				are rejected.
5. Claims					are objected to:
6. Claims					_ are subject to restriction or election requiremen
7. The formal	drawings filed on				are acceptable.
8. The drawing	g correction request file	ed on			has beenapproveddisapproved.
	gment is made of the cl	_		oplication,	serial no,
cordance w	pplication appears to boith the practice under E				ters, prosecution as to the merits is closed in ac-
11. Other					

- 14/0 --

2

Art Unit 125

The specification is objected to with regard to the statements on page 32, lines 23-26, 29 and 30 and page 37, lines 14-30 involving the treatment of Leukemia and cancer including melanocarcinomas, lung carcinomas and mammary tumors in mammals. Cancellation of said statements in mammals is in order. See In re Gattlieb, 140 USPQ at page 668.

Claims 82 and 83 are rejected as failing to define the invention under 35 USC 112, second paragraph. Claim 82 and 83 fail to differ in scope since the same composition is being claimed.

**GROUP ART UNIT 125** 

This action is made Final.

JGoldberg: jag

A/C 703

557-2575

12-8-80

- 141-